Live Breaking News & Updates on Genitourinary Cancers

Stay updated with breaking news from Genitourinary cancers. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Bristol Myers: EMA submission for colorectal cancer

Bristol Myers Squibb announces that the European Medicines Agency has validated its application for Opdivo + Yervoy as first-line treatment for adult patients with metastatic colorectal cancer with. ....

Bristol-myers-squibb , Dana-walker , European-medicines-agency , Global-head , Genitourinary-cancers , Bristol-myers , Markets ,

Early Responses With CTX130 Renew Hope for Anti-CD70 CAR T-Cell Therapy in Advanced RCC

Samer A. Srour, MB ChB, MS, explains the significance of early safety and efficacy data with CTX130 in CD70-expressing clear cell renal cell carcinoma. ....

United-states , Texas , Houston , Samera-srour , Division-of-cancer-medicine , Department-of-stem-cell-transplantation , University-of-texas-md-anderson-cancer-center , Stem-cell-transplantation , Cellular-therapy , Cancer-medicine , Cancer-center

CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

Recommendation based on results from CheckMate -901, the first Phase 3 trial with an immunotherapy-chemotherapy combination to demonstrate a survival benefit versus standard-of-care chemotherapy. ....

United-states , Japan , Taiwan , South-korea , China , Bristol-myers-squibb , Dana-walker , European-medicines-agency , Company-opdivo , Twitter , Instagram , Global-program

CHMP Recommends Frontline Nivolumab Plus Chemo in Unresectable/Metastatic Urothelial Carcinoma

Frontline nivolumab plus chemotherapy has been recommended for approval in unresectable or metastatic urothelial carcinoma. ....

Dana-walker , Bristol-myers-squibb-opdivo , European-commission , European-union , Bristol-myers-squibb , European-medicines-agency , Medicinal-products , Human-use , New-england-journal , Genitourinary-cancers ,

Bristol Myers: positive opinion from the CHMP for Opdivo

Bristol Myers Squibb announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the approval of Opdivo in combination with cisplatin. ....

Dana-walker , Bristol-myers-squibb , European-union , Global-program-leader , European-medicines-agency , Committee-for-medicinal-products-human-use , European-commission , Medicinal-products , Human-use , Vice-president , Genitourinary-cancers , Bristol-myers